Molecular Mechanisms Controlling NK Receptors

控制 NK 受体的分子机制

基本信息

  • 批准号:
    7932892
  • 负责人:
  • 金额:
    $ 37.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-01 至 2011-09-22
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Natural killer (NK) cells kill infected and malignant cells and direct subsequent adaptive immunity. NK cells distinguish normal from aberrant cells largely via killer cell immunoglobulin-like receptors (KIR). Despite high homology between KIR genes, individual NK cells express distinct numbers and combinations of clonally-restricted KIR (crKIR) genes. In contrast to crKIR, KIR2DL4 is expressed by all NK cells, preceding crKIR expression during NK development. The long-range goal is to use NK cells as effective treatments of cancer and infectious diseases. As the next logical step toward that goal, the current objectives are to further characterize KIR expression control in normal physiology and during epigenetic therapy of lymphoma and myelodysplastic syndrome. The rationale for the proposed research is that once KIR gene regulation is better understood, then KIR expression can be manipulated to make effective NK cells reagents in immunotherapy of cancer and infectious diseases. In this proposal, 2DL4 and crKIR promoters will be investigated, with special attention to mechanisms that overcome DNA methylation and repressive chromatin. Because so little is known about how lymphocyte-specific gene expression is influenced by cancer and by epigenetic therapy, we will study how DNA methylation and histone deacetylase inhibitor drugs affect KIR promoter methylation, KIR expression, and NK cell activation in myelodysplastic syndrome and lymphoma patients. This work may explain why NK function is poor in cancer patients and might suggest strategies for boosting immunity in these patients. We will catalog NK cell microRNA expression and their target mRNAs and we will investigate the microRNA mechanisms that regulate "dangerous" cytotoxic NK cells and "unlicensed" inhibitory receptor- negative NK cells. This will provide the basic information needed for future studies on control of NK developmental decisions in health and disease. This study will 1) develop a clear understanding of the multiple layers of regulation that control the initiation and maintenance of KIR expression; 2) establish for the first time how epigenetic therapy affects nonmalignant human lymphocyte gene expression and function in vivo; and 3) reveal NK-specific microRNA patterns and elucidate how they control mRNA targets to regulate NK development and set NK cell activation thresholds. These results will be highly significant, because they will be essential for understanding how NK cells distinguish normal from aberrant cells. Such an understanding will suggest new ways to manipulate NK cells in the therapy of cancer and infectious diseases. PUBLIC HEALTH RELEVANCE: Natural killer (NK) cells kill infected and malignant cells and direct subsequent adaptive immunity. The long-range goal is to use NK cells as effective treatments of cancer and infectious diseases. As the next logical step toward that goal, the current objectives are to further characterize NK gene expression control in normal physiology and in cancers and pre-cancers, such as lymphoma and myelodysplastic syndrome.
描述(由申请人提供):自然杀伤(NK)细胞杀死感染和恶性细胞,并指导随后的适应性免疫。NK细胞主要通过杀伤细胞免疫球蛋白样受体(KIR)区分正常细胞和异常细胞。尽管KIR基因之间具有高度同源性,但单个NK细胞表达不同数量和组合的克隆限制性KIR(crKIR)基因。与crKIR相反,KIR 2DL 4由所有NK细胞表达,在NK发育期间先于crKIR表达。长期目标是使用NK细胞作为癌症和传染病的有效治疗方法。作为实现这一目标的下一个合乎逻辑的步骤,目前的目标是进一步表征正常生理学和淋巴瘤和骨髓增生异常综合征的表观遗传治疗期间的KIR表达控制。这项研究的基本原理是,一旦更好地理解KIR基因调控,就可以操纵KIR表达,使NK细胞试剂有效地用于癌症和感染性疾病的免疫治疗。在这个提议中,2DL 4和crKIR启动子将被调查,特别注意克服DNA甲基化和抑制染色质的机制。由于对淋巴细胞特异性基因表达如何受癌症和表观遗传治疗的影响知之甚少,我们将研究DNA甲基化和组蛋白去乙酰化酶抑制剂药物如何影响骨髓增生异常综合征和淋巴瘤患者的KIR启动子甲基化、KIR表达和NK细胞活化。这项工作可以解释为什么NK功能在癌症患者中很差,并可能为这些患者提供增强免疫力的策略。我们将对NK细胞microRNA表达及其靶mRNA进行分类,并研究调节“危险”细胞毒性NK细胞和“未经许可”抑制性受体阴性NK细胞的microRNA机制。这将为今后的研究提供必要的基本信息,控制NK发展的健康和疾病的决定。这项研究将1)对控制KIR表达的启动和维持的多层次调控有一个清晰的认识; 2)首次建立表观遗传疗法如何影响体内非恶性人类淋巴细胞基因表达和功能; 3)揭示NK特异性microRNA模式,并阐明它们如何控制mRNA靶点来调节NK发育和设定NK细胞活化阈值。这些结果将是非常重要的,因为它们对于理解NK细胞如何区分正常细胞和异常细胞至关重要。这种理解将为在癌症和传染病的治疗中操纵NK细胞提供新的方法。公共卫生相关性:自然杀伤(NK)细胞杀死感染和恶性细胞,并指导随后的适应性免疫。长期目标是使用NK细胞作为癌症和传染病的有效治疗方法。作为实现这一目标的下一个合乎逻辑的步骤,目前的目标是进一步表征正常生理学和癌症及癌前病变(如淋巴瘤和骨髓增生异常综合征)中的NK基因表达控制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles T. Lutz其他文献

Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes.
用于检测 V 因子 Leiden (R506Q) 基因型的 PCR 方法的多中心评估。
  • DOI:
    10.1093/clinchem/44.6.1356
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    9.3
  • 作者:
    Charles T. Lutz;Paul A. Foster;Walter W. Noll;Karl V. Voelkerding;Richard D. Press;R. C. McGlennen;N. Kirschbaum
  • 通讯作者:
    N. Kirschbaum
Establishment of a reference interval for beta 2-microglobulin in cerebrospinal fluid with use of two commercial assays.
使用两种商业化验建立脑脊液中 β2-微球蛋白的参考区间。
  • DOI:
  • 发表时间:
    1991
  • 期刊:
  • 影响因子:
    9.3
  • 作者:
    Charles T. Lutz;Steven H. Cornell;James A. Goeken
  • 通讯作者:
    James A. Goeken
Allergy testing of multiple patients should no longer be performed with a common syringe.
不应再使用共用注射器对多名患者进行过敏测试。
  • DOI:
    10.1056/nejm198405173102024
  • 发表时间:
    1984
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Charles T. Lutz;C. Elliott Bell;H. Wedner;Donald J. Krogstad
  • 通讯作者:
    Donald J. Krogstad

Charles T. Lutz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles T. Lutz', 18)}}的其他基金

Muscle, Fat and NK Lymphocytes in Aging
衰老过程中的肌肉、脂肪和 NK 淋巴细胞
  • 批准号:
    8517537
  • 财政年份:
    2012
  • 资助金额:
    $ 37.46万
  • 项目类别:
Muscle, Fat and NK Lymphocytes in Aging
衰老过程中的肌肉、脂肪和 NK 淋巴细胞
  • 批准号:
    8384461
  • 财政年份:
    2012
  • 资助金额:
    $ 37.46万
  • 项目类别:
Natural Killer Subset Senescence and Clonality in Aging
自然杀手亚群衰老和衰老过程中的克隆性
  • 批准号:
    7286019
  • 财政年份:
    2006
  • 资助金额:
    $ 37.46万
  • 项目类别:
Natural Killer Subset Senescence and Clonality in Aging
自然杀手亚群衰老和衰老过程中的克隆性
  • 批准号:
    7143838
  • 财政年份:
    2006
  • 资助金额:
    $ 37.46万
  • 项目类别:
Immune Senescence: Molecular Mechanisms, Diets & Stress
免疫衰老:分子机制、饮食
  • 批准号:
    7040769
  • 财政年份:
    2004
  • 资助金额:
    $ 37.46万
  • 项目类别:
Molecular Mechanisms Controlling NK Receptors
控制 NK 受体的分子机制
  • 批准号:
    7729934
  • 财政年份:
    2003
  • 资助金额:
    $ 37.46万
  • 项目类别:
Molecular Mechanisms Controlling KIR Genes in NK Cells
NK 细胞中控制 KIR 基因的分子机制
  • 批准号:
    6897731
  • 财政年份:
    2003
  • 资助金额:
    $ 37.46万
  • 项目类别:
Molecular Mechanisms Controlling KIR Genes in NK Cells
NK 细胞中控制 KIR 基因的分子机制
  • 批准号:
    7188084
  • 财政年份:
    2003
  • 资助金额:
    $ 37.46万
  • 项目类别:
Molecular Mechanisms Controlling NK Receptors
控制 NK 受体的分子机制
  • 批准号:
    8224060
  • 财政年份:
    2003
  • 资助金额:
    $ 37.46万
  • 项目类别:
Molecular Mechanisms Controlling KIR Genes in NK Cells
NK 细胞中控制 KIR 基因的分子机制
  • 批准号:
    7032231
  • 财政年份:
    2003
  • 资助金额:
    $ 37.46万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.46万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了